$LIDR

AEye, Inc. (LIDR): Results of Operations and Financial Condition

AEye, Inc. (LIDR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030082701ex99-1.htm PRESS RELEASE DATED AUGUST 6, 2026 Exhibit 99.1 AEye Reports Second Quarter 2026 Results; Commercial Pipeline Again Reaches Record Level Q2 Revenue Approximately Doubled Sequentially and Grew Approximately Nine-Fold Year-Over-Year; First-Half Reven

Original reporting
Published Aug 6, 2026, 8:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$LIDR
Bullish
medium confidence
Mentioned
$LIDR
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$LIDRBullishMed
01

Why it matters

Traders can update models around revenue ramp trajectory, loss trajectory, and cash runway through 2028, while monitoring whether the new vertical wins translate into sustained paid shipments.

02

Market read

Fresh quarterly numbers plus a cash burn outlook and multiple commercial milestones create a tradable catalyst ahead of the scheduled investor call.

03

What to watch

Cash consumption is guided for 2026, but the article does not provide gross margin, backlog size, or timing of larger commercial shipments, which are key for valuation and near-term estimates.

Relevance 7/10Novelty 8/10Timing: investor webcast today at 2:00 p.m. PT

Background

This is an SEC 8-K with Exhibit 99.1 press release covering AEye’s Q2 2026 financial results and commercial updates across sports analytics, defense, automotive evaluations, and ITS deployments.

Company-level read

Ticker impact

$LIDRBullishMedium confidence
Context

AEye reported Q2 2026 results with revenue up about 9x YoY, record commercial engagement, and a reaffirmed 2026 cash-consumption outlook.

Expected impact

Potentially positive bias for the stock into/after the scheduled investor call, but magnitude likely tempered by continued losses and small absolute revenue.

Evidence & confidence

New primary disclosure includes Q2 revenue, GAAP and non-GAAP net loss, cash balance, cash consumption guidance, and specific commercial wins (sports analytics deal, NVIDIA DRIVE AGX Thor validation, third consecutive defense order).

Market effects

Reinforces the narrative that software-defined lidar and sensor-to-compute validation (NVIDIA DRIVE) can unlock new verticals beyond defense.

Limited direct regional read-through; mentions Bay Area ITS deployment and Detroit installations.

Defense and international reach expansion via SynTech suggests potential cross-border procurement momentum.

Counterpoint

Despite record engagement, Q2 revenue remains very small in absolute dollars ($202k), so the stock may still be highly sensitive to execution risk and dilution expectations.

Key entities

  • AEye, Inc.

    Nasdaq-listed lidar software company reporting Q2 2026 results and commercial traction, including sports analytics and defense repeat orders.

  • NVIDIA DRIVE AGX Thor

    Platform on which Apollo was validated, supporting sensor-to-compute interoperability claims.

  • Alive3D

    Selected Apollo for next-generation sports analytics, per the company’s commercial deal disclosure.

  • SynTech

    Partnership referenced as expanding Apollo’s international reach in defense.

  • MoveAWheeL

    MOU partner combining Apollo long-range 3D detection with acoustic road-surface friction sensing for ADAS/autonomy.

Related articles

$LIDRMedAI 8/10

AEye (LIDR) Q2 2026 Earnings Call Transcript

AEye (LIDR) reported Q2 2026 revenue of $202,000, up ninefold YoY and 100% vs Q1, with first-half revenue of $303,000. It had 25 revenue-generating customers. GAAP net loss was $10.0 million ($0.22/share). Cash and marketable securities were $71.5 million. Management guided full-year cash use of $30M to $35M.

$BBNMed

Baby Bunting posts 33.9% rise in fiscal 2026 profit

Baby Bunting Group Ltd reported fiscal 2026 pro forma net profit of A$16.1m, up 33.9% from A$12.1m, on revenue of A$556.0m (+6.5%). Comparable sales rose 3.5%. Gross margin increased to 41.2%, and online sales were A$140.5m (25.3%). The company opened seven stores, reaching 80 outlets, and did not declare a final dividend.

$RICKMed

RCI Hospitality Holdings (RICK) Q3 2026 Earnings Call Transcript

RCI Hospitality Holdings (RICK) reported Q3 2026 operating income of $19.6M vs $17.9M, with segment margin 31.2% vs 28.6%. Non-GAAP operating income was $20.2M vs $20.8M. Bombshells revenue rose 25.4% to $10.8M. Cash was $26.4M; debt paydowns were $8.6M and $1M of share buybacks. Debt-to-EBITDA was 4.3x (3.7x excluding a legal accrual).

$ALLTMed

Allot Ltd (ALLT) (Q2 2026) Earnings Call Highlights: Revenue Surges 15%

Allot Ltd (ALLT) reported Q2 2026 earnings call highlights. Management said revenue rose 15% and strength came from both CCaaS and its smart product line. CEO Eyal Harari said backlog remains at a very high level. CFO Liat Nahum cited deferred revenue increasing by $7.5M QoQ plus $13.4M from Q1, improving visibility for 2026-27, and discussed a share buyback.

$ILLMFMedAI 8/10

Illumin Holdings Inc (ILLMF) (Q2 2026) Earnings Call Highlights: Record Revenue and Return

Illumin Holdings (ILLMF) reported Q2 2026 record revenue of $50.2 million, up 52% year over year, driven by a 108% jump in its exchange business to $27.1 million. Gross profit rose 24% to $17.6 million, while gross margin fell to 35.1%. Operating expenses declined to $18.7 million, producing net income of $19,000 versus a $5.8 million loss in Q2 2025. The firm ended with $33.7 million cash, no debt, paused its NCIB, and expects double-digit growth into Q3.

$AMSMed

American Shared Hospital Services (AMS) (Q2 2026) Earnings Call Highlights: Strong

American Shared Hospital Services (AMS) reported Q2 2026 earnings call highlights including 19% year-over-year revenue growth driven by direct patient services, higher international Gamma Knife volumes, and improving proton beam performance. Proton beam revenue rose 22% to about $2.3M in the quarter and $4.3M for six months. Reported results were impacted by $285k legal costs and a $909k credit-loss allowance. Cash equivalents and restricted cash were about $6.8M.